Abinopharm says NMN trial eased post-exercise inflammation

By AI, Created 4:47 PM UTC, May 18, 2026, /AGP/ – Abinopharm says a randomized, double-blind human trial found its AbinoNutra® NMN supplement was safe and well-tolerated in young male athletes at a 1,200mg daily dose. The company says the study also showed reduced exercise-induced inflammation and changes in skeletal-muscle mitochondrial balance, a potential signal for sports recovery and longevity markets.

Why it matters: - Abinopharm is positioning AbinoNutra® NMN as a sports nutrition ingredient with clinical backing, not just a longevity supplement. - The company says the findings could support post-exercise recovery claims and broaden NMN’s commercial appeal. - The study adds human data to a category often marketed with limited clinical evidence.

What happened: - Abinopharm announced detailed results from a randomized, double-blind, placebo-controlled human clinical trial on oral AbinoNutra® NMN. - The study enrolled healthy men ages 20 to 30. - Participants took 1,200mg of AbinoNutra® NMN daily, delivered as four 300mg capsules. - The trial examined skeletal muscle health after blood flow restriction exercise.

The details: - The primary endpoints measured inflammation markers and mitochondrial content in skeletal muscle. - Abinopharm says the trial found AbinoNutra® NMN was safe and well-tolerated at 1,200mg per day. - The company says the trial showed a significant reduction in exercise-induced inflammation. - The company says the study also found optimization of mitochondrial balance in skeletal muscle. - Professor Chia-Hua Kuo, the lead researcher, said exercise activates inflammation and NMN helps lower it. - The clinical data was published in a peer-reviewed paper on the National Center for Biotechnology Information site: the published study - NutraIngredients.com highlighted the study’s potential implications for the sports nutrition industry in a separate report: the full report

Between the lines: - The timing suggests Abinopharm is trying to move NMN from a general wellness category into performance and recovery use cases. - The use of a relatively high 1,200mg dose gives the company a concrete benchmark for future product positioning. - The study’s focus on young male participants limits how broadly the results can be applied without more data. - The cited mitochondrial findings may interest longevity researchers, but the practical performance impact is not established by the release alone.

What’s next: - Abinopharm says the trial is part of a multi-national clinical program that includes studies in Japan and Singapore. - The company says collaborations are upcoming with Yale University and the National University of Singapore. - Abinopharm plans to continue building its clinical evidence base for AbinoNutra® NMN and Dr.Ergo® L-Ergothioneine.

The bottom line: - Abinopharm is using human trial data to argue that AbinoNutra® NMN is both safe and potentially useful for recovery-focused sports nutrition. The bigger question is whether broader studies confirm the same effects in more diverse populations.